Merck to pay $1.5M over environmental issues; APIs to star in next round of Big Pharma deal-making in India;

> Merck ($MRK) will pay a $1.5 million civil penalty to settle alleged violations of federal environmental laws--failing to take certain preventive measures, and noncompliance with reporting regulations--at two Pennsylvania facilities. Story

> Watch for active pharmaceutical ingredients to be at the center of coming M&A deals among Big Pharma and Indian drugmakers.  More

> The search for new cancer treatments is being sidetracked because pharma companies are unable to keep up with demand for clinical trial supplies. Story

> Pfizer ($PFE) and the National Association of Boards of Pharmacy have paired up to warn consumers about the risks of counterfeit prescription drugs. Item

> Roche last week cut the ribbon on a 17,000-square-foot clinical supply manufacturing facility at its Nutley, NJ campus, capable of producing dosage forms of highly potent compounds. Release

> H&P Industries has updated its March recall of Povidone Prep Pads to include Lee Medical International's Custom Dialysis Trays/Kits. Release

> Emergent BioSolutions ($EBS) has been awarded a 5-year contract to supply the U.S. government with 44.8 million doses of the BioThrax anthrax vaccine; total value could reach $1.25 billion. Release

> CryoPort ($CYRX) and MediRent will open a European Operations Center in Leiden, The Netherlands. Announcement

Suggested Articles

A biotech that worked with a nutritional products maker on the API for its clinical-stage radiation drug, is buying all of the manufacturing know-how.

Merck KGaA is selling a manufacturing site and its Allergopharma allergy drug business as it focuses on newer meds.

In a first, the FDA and Indian oversight agencies worked together to block illegal drugs from entering the U.S.